First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC.

British journal of cancer

Volumn 110, Issue 8, 2014, Pages 1917-1922

  Ko, J J ^a   Choueiri, T K ^a   Rini, B I ^a   Lee, J L ^a   Kroeger, N ^a   Srinivas, S ^a   Harshman, L C ^b   Knox, J J ^b   Bjarnason, G A ^a   MacKenzie, M J ^b   Wood, L ^a   Vaishampayan, U N ^b   Agarwal, N ^b   Pal, S K ^a   Tan, M H ^a   Rha, S Y ^b   Yuasa, T ^b   Donskov, F ^b   Bamias, A ^b   Heng, D Y ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGED; ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DRUG ANTAGONISM; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; METASTASIS; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84901844215     PISSN: None     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.25     Document Type: Article

References (0)